All News
Filter News
Found 8,248 articles
-
ORI Capital announced Thursday that it has raised more than a quarter of a billion dollars for its second life sciences fund, which will invest in early-stage biotech companies using the firm’s proprietary AI-driven platform.
-
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
2/22/2024
Danaher Corporation announced it has committed to set science-based greenhouse gas emission reduction targets in line with the Science Based Targets initiative, including a long-term target to reach net-zero value chain emissions by no later than 2050.
-
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
2/22/2024
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results.
-
Evolent Announces Fourth Quarter and Full Year 2023 Results
2/22/2024
Evolent Health, Inc. (NYSE: EVH) today announced financial results for the three months and year ended December 31, 2023.
-
Otolith Labs Expands Leadership Team with the Appointment of Dan Wagner as its Chief Commercial Officer and Raphael Michel to its Board of Directors
2/21/2024
Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Dan Wagner as Chief Commercial Officer and Raphael Michel as an independent Board member.
-
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
2/21/2024
Emergent BioSolutions Inc. today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024.
-
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
2/21/2024
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2023 financial results.
-
MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment
2/20/2024
MediThinQ, a pioneering Korean startup specialising in extended reality wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays.
-
NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
2/20/2024
NRx Pharmaceuticals, Inc. today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City.
-
Firefly Bio Debuts With $94 Million Series A Financing
2/15/2024
Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
-
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
2/15/2024
Poolbeg Pharma announces a change of Board role and the Remuneration Committee's approval of the adoption of an Employee Performance Incentive Plan for a number of the key senior management, to align medium and long term objectives with those of shareholders and to encourage retention.
-
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
2/15/2024
iNtRON Biotechnology has announced that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF, a harmful microbe associated with colorectal cancer.
-
BioHarvest Sciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
2/15/2024
BioHarvest Sciences Inc., (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a biotechnology company pioneering botanical synthesis, has engaged investor relations specialists
-
The neuroscience space saw a late push in merger and acquisition activity, while oncology start-ups reeled in the most venture capital funds. Industry leaders expect these trends to continue.
-
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
2/14/2024
Ocuphire Pharma, Inc. today announced the appointments of Ash Jayagopal, Ph.D. M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.
-
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
2/14/2024
Autonomix Medical, Inc reported financial results yesterday for the third quarter FY2024 ended December 31, 2023 and provided a corporate update.
-
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
2/13/2024
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”) today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share.
-
Shares of preclinical genetic medicines company Metagenomi tanked more than 30% on Friday afternoon in a disappointing debut for its initial public offering, bucking the trend of positive IPOs so far this year.
-
Despite not having a single candidate in the clinical stage, the Moderna-backed biotech is offering 6.25 million shares for $15 apiece in an initial public offering. Shares are expected to begin trading Friday.
-
Investors drove up the price of Kyverna Therapeutics’ stock by 59% in its initial public offering on Thursday afternoon, the first day of trading, reaching a peak per-share price of $35.01.